Creative Touch Permanent Makeup and Aesthetics

Barrier dysfunction exists on a spectrum rather than as a binary state. Early compromise is characterised by subclinical reductions in stratum corneum integrity – measurable as increased transepidermal water loss before overt sensitivity or reactivity appears. If triggers are not removed and the lipid matrix is not supported, a self-perpetuating feedback loop develops: barrier disruption activates keratinocyte cytokine release ( IL-4, IL-13, IL-31, IL-33), which directly suppresses filaggrin expression and the elongase enzymes responsible for ceramide synthesis, preventing the barrier from producing the components it needs to repair. This cycle cannot resolve through barrier support alone once it is established – the inflammatory signals driving it must be addressed simultaneously. Chronic barrier dysfunction represents the stabilised endpoint of this loop, where persistent subclinical inflammation maintains the damaged state indefinitely without intervention.

The Barrier Function Spectrum

Barrier dysfunction is not a threshold event, it exists on a measurable continuum from subclinical compromise through to established chronic dysfunction. TEWL (transepidermal water loss) is the objective clinical marker: healthy facial skin baseline sits at approximately 8–12 g·m⁻²·h⁻¹, with disrupted atopic skin showing values of 28.68 ± 14.28 g·m⁻²·h⁻¹ compared to 11.60 ± 7.78 g·m⁻²·h⁻¹ in healthy controls – more than double the baseline. ^[5] The clinically important insight is that structural compromise is measurable and progressing before a client notices any subjective change. By the time tightness, sensitivity, or product intolerance becomes apparent, barrier integrity has already declined significantly.

The three stages that matter clinically:

• Early compromise: Measurable TEWL increase, subclinical lipid matrix disruption, no subjective symptoms or mild tightness only. The barrier is impaired but the inflammatory feedback loop has not yet engaged. Trigger removal and lipid support at this stage can reverse the trajectory without anti-inflammatory intervention.
• Active dysfunction: Subjective sensitivity, reactivity to previously tolerated products, visible redness or irritation. The IL-4/IL-13 suppression of filaggrin and ceramide synthesis has begun, meaning the barrier is losing its capacity to self-repair. Both barrier support and inflammatory signal reduction are now needed simultaneously.
• Chronic dysfunction: A stabilised impaired state where persistent low-grade inflammation maintains ongoing filaggrin and ceramide synthesis suppression. Without external intervention the loop sustains itself indefinitely. Topical barrier support alone is insufficient; upstream interruption of the cytokine signals is required.

Early Compromise Triggers

The initial impairment that starts the progression can come from multiple directions, often acting simultaneously:

Surfactants and cleansing products: Surfactants interact with the intercorneocyte lipid matrix directly, disrupting the lamellar structure and increasing SC permeability. Hard water compounds this significantly – the combination of sodium lauryl sulphate with hard water calcium ions increases SLS deposition on the skin surface, measurably elevating TEWL and causing irritation even in non-sensitised individuals. The effect is disproportionately stronger in those with FLG mutations, where baseline barrier integrity is already reduced. ^[3]

pH disruption: The stratum corneum maintains an acid mantle at approximately pH 4.5–5.5 that is essential for the serine proteases (kallikreins) regulating corneocyte desquamation and the β-glucocerebrosidase and sphingomyelinase enzymes that process lipid precursors into functional barrier ceramides. Alkaline cleansers raise the SC pH, impairing both enzyme pathways simultaneously – accelerating excessive desquamation and reducing ceramide synthesis in the same action.

Hormonal change: Declining oestrogen during perimenopause reduces ceramide synthesis capacity, sebum production, and epidermal lipid organisation independently of any external trigger – creating a constitutive barrier vulnerability that makes early compromise more likely from exposures that previously caused no problem. This mechanism is covered in full in the Perimenopausal Skin Changes entity.

Cortisol elevation: Sustained cortisol elevation inhibits HMG- CoA reductase, the enzyme responsible for cholesterol synthesis. Cholesterol is a structural component of the SC lipid bilayer in approximately equimolar proportion with ceramides and free fatty acids; its shortfall impairs the bilayer’s integrity and measurably delays barrier recovery after disruption. The TEWL research on stress-impaired barrier recovery demonstrates significantly longer recovery times in psychologically stressed individuals following controlled barrier disruption, directly confirming that the HPA axis translates into stratum corneum function. This mechanism is covered in full in the Cortisol and Skin entity.

The Self-Perpetuating Feedback Loop

Once barrier compromise progresses beyond the early stage, keratinocyte signalling takes over and the trajectory changes fundamentally. Stratum corneum disruption activates keratinocytes to release thymic stromal lymphopoietin (TSLP), IL-33, and IL-25, which drive Type 2 immune cell activation and the release of IL-4, IL-13, and IL-31 into the dermal and epidermal environment. ^[1]

These cytokines then directly suppress the two synthesis pathways the barrier needs to repair itself:

IL-4 and IL-13 suppress filaggrin expression via STAT6 activation, reducing the production of the protein responsible for corneocyte structural integrity, natural moisturising factor (NMF), and the maintenance of the acidic pH environment ceramide-processing enzymes require. ^[6]

IL-4 and IL-13 suppress the elongase enzymes (ELOVL1, ELOVL4) responsible for producing the very-long-chain fatty acids that are esterified into the ceramide species most critical for barrier function – specifically acylceramides, which form the corneocyte lipid envelope. Without adequate acylceramide production, lamellar body secretion is impaired and the SC lipid bilayer develops structural gaps. ^[1]

IL-31 drives the itch-scratch cycle that provides an additional mechanical disruption pathway running in parallel with the cytokine-mediated lipid synthesis failure.

The result is a closed loop: barrier disruption → cytokine release → synthesis suppression → less filaggrin and fewer ceramides → reduced barrier function → more disruption → more cytokine release. The loop is self-sustaining because the inflammatory signal that prevents repair is generated by the damage that requires it.

When Barrier Dysfunction Becomes Chronic

Chronic barrier dysfunction represents the stabilised endpoint of this loop – a state where low-grade persistent inflammation has become the skin’s baseline. Clinically this presents as perennial sensitivity, unpredictable reactivity, complete intolerance of actives that the skin previously handled, and a texture that appears permanently stressed. Products that address the lipid deficit – ceramide formulations, fatty acids – may produce modest temporary improvement but cannot hold it, because the cytokine environment is constantly re-suppressing the synthesis they are supplementing.

The additional compounding mechanism at this stage is the SASP dimension in older skin. Chronic barrier inflammation increases dermal cytokine burden, which accelerates fibroblast senescence in the dermis below – connecting persistent epidermal dysfunction to the deeper structural collagen decline mechanisms described in the Fibroblast entity. The barrier and the dermis are not independent layers; chronic barrier inflammation degrades both.